Submit your PPH claim details for a free, no obligation case review
Get Started:
Flolan is currently the only FDA approved drug for the treatment of primary pulmonary hypertension (PPH). Expected to raise the life expectancy of patients suffering from PPH, Flolan has extended the lives of patients using the drug by 3-5 years or more. PPH patients must continue the Flolan therapy for the rest of their lives with a regular increase in dosage. PPH causes a dangerously high blood pressure level in the pulmonary artery that connects the heart and lungs, leading to the heart being destroyed in some instances.
Primary pulmonary hypertension is a serious and non-curable disease that is predicted to increase according to medical researchers as a result of the high number of Fen Phen users. An estimated at 6-7 million people in the U.S. used Fen Phen and due to the 4-6 year latency period between Fen Phen use and PPH symptoms, diagnosis was often delayed. PPH sufferers will sometimes use Flolan or Tracleer therapy to prolong their life expectancy.
Copyright © 2001 - 2009 Online Lawyer Source | Legal Marketing Site Designed by eJustice